Description

Pharmacological action of the drug Ebixa 10 mg

A remedy for the treatment of dementia. It is a non-competitive antagonist of glutamate NMDA receptors (including in the substantia nigra), as a result, it reduces the excessive stimulating effect of cortical glutamate neurons on the neostriatum, which develops against the background of insufficient release of dopamine. By reducing the flow of Ca2+ into neurons, it reduces the possibility of their destruction.

It has nootropic, cerebrovasodilating, antihypoxic and psychostimulating effects.

Improves impaired memory, increases the ability to concentrate, reduces fatigue and symptoms of depression, reduces spasticity of skeletal muscles caused by diseases or brain damage.

Indications of the active substances of the drug Ebixa

Moderate to severe dementia in Alzheimer’s disease.

Contraindications for use

Hypersensitivity to memantine; severe liver failure; pregnancy; lactation period (breastfeeding); children and adolescents under 18 years of age (efficacy and safety of the drug have not been established).

With caution: epilepsy, thyrotoxicosis, predisposition to develop seizures, simultaneous use of NMDA receptor antagonists (amantadine, ketamine, dextromethorphan), factors that increase urinary pH (abrupt change in diet, for example, switching to vegetarianism, abundant intake of alkaline gastric buffers), renal tubular acidosis, severe urinary tract infections caused by Proteus spp., myocardial infarction (history), heart failure, uncontrolled arterial hypertension, renal failure, mild or moderate liver failure (Child-Pugh class A and B).

Dosage and administration

When taken orally, the initial dose for adults is 5 mg / day. In the future, the dose can be increased weekly by 5 mg. The average maintenance dose is 10-20 mg / day. The maximum dose is 20 mg / day.